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Introduction
This presentation is a focus on some of
the theories of the pathophysiology of
early-onset Alzheimer’s Disease (AD) in
individuals with Down Syndrome (DS).
Down Syndrome, a genetic condition
where an individual has a partial or full
extra chromosome 21, is the most
common chromosomal condition in the
United States (National Down Syndrome
Society (NDSS), 2012). Average life
expectancy for individuals with DS has
vastly increased in the last thirty years
from age 25 to age 60 (NDSS, 2012). The
extra chromosome genetically makes
individuals with DS predisposed to certain
conditions, including early onset dementia
and AD, therefore as their life expectancy
increases, so does their risk of developing
this disease. Early-onset AD is
characterized by having AD by the age 65.
The purpose of this presentation is to aid
practitioners in having a better
understanding of the disease process in
order to provide appropriate and timely
diagnosis and treatment for this growing
population.

Pathophysiological
Processes
All individuals with DS, by the age of 40,
will develop neuropathological changes of AD,
including the hallmark signs of amyloid
plaques and neurofibrillary tangles (NFTs)
(Head et. Al, 2011). This neuropathological
presentation has been attributed to the
triplication and overexpression of the gene for
amyloid precursor protein (APP), which is
located on chromosome 21 (Jones et. al, 2011).
This does not count for the entire picture, so
other contributing factors must be explored.

.

Signs and Symptoms

Underlying Pathophysiology

Alzheimer’s Association (2014) describes the early
presentation of AD as difficulty in remembering newly
learned information, with advances stages potentially
presenting with mood or behavior changes,
disorientation, more severe memory loss, and difficulty
in walking, speaking, and swallowing. In individuals
with DS, other symptoms of AD may appear first,
especially behavior and mood changes. Ball, Holland,
Watson and Huppert (2011) state that “preclinical
stages of AD , as it develops in people with DS, are
marked by changes in personality and behavior,
associated with a specific impairment in the cognitive
functions subserved by the frontal lobes” (p.321).
Diagnosis in individuals with DS can also be difficult
because the tasks performed in standard testing may
not be possible for these individuals to perform.
The Alzheimer’s Association (2014) provides the
following early symptoms of AD in individuals with DS:
•
Reduced interest in being sociable, conversing or
expressing thoughts
•
Decreased enthusiasm for usual activities
•
Decline in ability to pay attention
•
Sadness, fearfulness or anxiety .
•
Irritability, uncooperativeness or aggression
•
Restlessness or sleep disturbances
•
Seizures that begin in adulthood
•
Changes in coordination and walking
•
Increased noisiness or excitability

AD is not completely understood, including in individuals with
DS, however there are some known processes, including amyloid
plaques and neurofibrillary tangles, and there are several additional
theories to explain the processes of AD and early-onset AD beyond
that. It is known that all individuals with DS have a partial or full
triplication of chromosome 21, as well as amyloid plaques and NFTs
by the age of 40. The following are examples of suggested theories
to AD, AD in DS and early-onset AD:
•
Head et al. (2011) state that the amyloid plaques contain the
amyloid Beta peptide that is derived from a longer precursor
protein, amyloid Beta protein precursor, the gene for which is
on chromosome 21. Overexpression by triplication of this
chromosome is suggested to be the cause of the excessive
amyloid plaques in individuals with DS.
•
Serano-Pozo, Frosch, Masliah, and Hyman (2011) state that
neuropathological changes that occur in any AD include
abundant amyloid plaques, neurofibrillary tangles along with
neuropil threads, dystrophic neurites containing
hyperphosphorylated tau that are accompanied by astroglials
and microglial cell activation leading to the characteristic
losses of neurons, nueropils, and synaptic elements. They
also argue the neuroanatomical changes begin to accumulate
ten years or more prior to the dementia diagnosis, making
early detection of these changes important for early
treatment.
•
Jones, Margallo-Lana, Prasher, and Ballard (2008) suggest that
the pathology consists of amyloid plaques, and NFTs with
hyperphosphorylated tau in the form of paired helical
elements. They state that a tetranucleotide repeat in intron 7
of APP has been associated with an earlier onset of dementia
(Jones, Margallo-Lana, Prasher, and Ballard, 2008). The
relevance of this to DS is that this is located on chromosome
21, which is triplicated in DS.
•
Jones et al. do a later study that further discusses APP. The
study states that APP is expressed in DS at levels four to five
times higher than the general population (Jones et.al, 2011).
They claim that the regulators of APP expression are also
located on chromosome 21. The processing of APP results in
production of beta amyloid which is deposited extracellularly
in the brain, found as a core disease feature in people with AD
(Jones et al., 2011).
•
Wilcock and Griffin (2013) state that overexpression of APP
and S100B and resultant overexpression of the pluripotent
neuroinflammatory cytokine IL-1 end in multiple neural
results that is characterized by gliosis-related
neuroinflammation and the neuropathological changes of AD.
S100B is an astrocyte-derived cytokine, encoded by
chromosome 21 and is markedly elevated through life in
individuals with DS.
•
Ball, Holland, Watson and Huppert (2010) also explore the
effects of SB100 in that it is involved in mediating growth of
serotonin neurons. The study also revealed that individuals
with DS who were on antidepressants was significantly
associated with better performance in working memory tests.
•
Coskun et al. (2010) proposed that etiology of premature
dementia is the result of an underlying mitochondrial
dysfunction resulting in energetic deficiency, increased
oxidative stress, altered Calcium regulation, and predication
to cell death through activation of mtPTP, resulting in a loss of
neuronal process and neurons.

Epidemiology
As previously discussed, all individuals
with DS develop neuropathological changes
of AD. Mean age of clinical diagnosis of AD in
DS individuals is 51+/- 6 (Alvarez, Hoffmann,
Hauser & Talavera 2014). A review of studies
showed that 10-25% of patients had AD when
aged 40-49 years, 20-50% had AD when aged
50-59 years, and 60-75% had AD when older
than 60 years (Alvarez, Hoffmann, Hauser &
Talavera, 2014)

Georgia Gwinnett, 2010.

Significance of
Pathophysiology

Implications for
Nursing Care

It is known that AD is partially a
resultant of amyloid plaques and NFTs,
and that individuals with DS will acquire
both of these before the age of 40.
Several studies have been done to suggest
that there are other factors that play a
role in early onset AD. It has been
reported that early-onset AD in a general
population is of the familial type,
suggesting that the problem lies
somewhere within genes. The
significance of the pathophysiology in
individuals with DS is that the triplication
of chromosome 21 causes overexpression
of proteins and other materials that lead
to amyloid plaques and NFTs at an early
age. The further study of individuals with
DS can hold the key to answer questions
that are still unanswered about the
pathophysiology of early-onset AD and AD
in general. Further studies could also
explore the potential effects of selective
serotonin reuptake inhibitors.

Since it is known that all individuals
with DS will have neuropathological
features of AD, it is pertinent that health
care professionals monitor for signs of
cognitive change at an early age. A
baseline cognitive and behavioral
assessment should be performed on the
DS individual by the age of 35 with an
annual screening starting at age 40. Early
signs of dementia and AD often go
unnoticed in individuals with DS due to
their atypical presentation of behavioral
changes instead of memory impairment.
Behavioral changes are also often
attributed in the DS population as part of
their developmental disability. Whitwan,
McBrien, and Broom (2010) developed a
standardized screening checklist to help
health care professionals know when to
make a referral for a dementia
assessment for individuals with DS and
other developmental disabilities.

Conclusion
Every individual with DS will have the AD hallmark diagnostic criteria of amyloid
plaques and NFTs by the age of 40. The triplication of chromosome 21 that is
characteristic of DS causes overxpression of genetic materials that contribute to this.
This makes it evident that chromosome 21 is a primary factor that contributes to the
development of AD. Further focused studies on the role that chromosome 21 plays
in individuals with early onset AD can potentially be used to develop targeted drugs
to stop of slow down the process.

Brain Scan Comparison of Individuals with DS and AD,
Ghose, 2011.
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